Harbin Medisan Pharmaceutical Co., Ltd.
Символ: 002900.SZ
SHZ
9.91
CNYПазарна цена днес
44.8594
Съотношение P/E
1.3177
Коефициент PEG
3.07B
MRK Cap
- 0.01%
Доходност на DIV
Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4989.65 | 1293.9 | 1111.5 | 1022.2 | |||||||||||
balance-sheet.row.short-term-investments | 323.39 | 91.3 | 581.7 | 360.8 | |||||||||||
balance-sheet.row.net-receivables | 737.24 | 164.1 | 149.6 | 204.7 | |||||||||||
balance-sheet.row.inventory | 690.81 | 161.2 | 156.5 | 186.5 | |||||||||||
balance-sheet.row.other-current-assets | 25.17 | 4.5 | 9.5 | 26.7 | |||||||||||
balance-sheet.row.total-current-assets | 6442.89 | 1623.7 | 1427.2 | 1440.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 3763.75 | 882.4 | 925.3 | 867.3 | |||||||||||
balance-sheet.row.goodwill | 2.84 | 0.5 | 9.4 | 9.4 | |||||||||||
balance-sheet.row.intangible-assets | 397.31 | 71.7 | 62.5 | 66.4 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.15 | 72.2 | 71.9 | 75.9 | |||||||||||
balance-sheet.row.long-term-investments | 2342.44 | 555.6 | 22.8 | -345.9 | |||||||||||
balance-sheet.row.tax-assets | 96.63 | 23.8 | 25.8 | 23.9 | |||||||||||
balance-sheet.row.other-non-current-assets | 424.95 | 119.1 | 592.4 | 421.4 | |||||||||||
balance-sheet.row.total-non-current-assets | 7027.92 | 1653.1 | 1638.3 | 1042.6 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 13470.8 | 3276.8 | 3065.5 | 2482.8 | |||||||||||
balance-sheet.row.account-payables | 599.61 | 120.8 | 105.2 | 90 | |||||||||||
balance-sheet.row.short-term-debt | 1288.91 | 233.8 | 274.8 | 269.8 | |||||||||||
balance-sheet.row.tax-payables | 33.31 | 12.2 | 11.2 | 10.8 | |||||||||||
balance-sheet.row.long-term-debt-total | 1494.36 | 422.9 | 212.9 | 10.9 | |||||||||||
Deferred Revenue Non Current | 329.34 | 83.9 | 89 | 88.7 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 498.99 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 416.3 | 188.3 | 2.5 | 2.1 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 2322.69 | 627.1 | 412.4 | 102.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 20.03 | 5.1 | 8 | 10.9 | |||||||||||
balance-sheet.row.total-liab | 5113.11 | 1224.8 | 949 | 691.2 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 1266.32 | 316.6 | 316.6 | 316.6 | |||||||||||
balance-sheet.row.retained-earnings | 2371.06 | 570.7 | 639.6 | 341.2 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2777.02 | 162.5 | 192.3 | 164.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1903.32 | 990.9 | 952.9 | 952.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 8317.72 | 2040.7 | 2101.4 | 1775.3 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 13470.8 | 3276.8 | 3065.5 | 2482.8 | |||||||||||
balance-sheet.row.minority-interest | 39.97 | 11.3 | 15 | 16.3 | |||||||||||
balance-sheet.row.total-equity | 8357.69 | 2052 | 2116.5 | 1791.6 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 13470.8 | - | - | - | |||||||||||
Total Investments | 2665.83 | 646.9 | 604.5 | 14.9 | |||||||||||
balance-sheet.row.total-debt | 2783.27 | 656.7 | 487.7 | 269.8 | |||||||||||
balance-sheet.row.net-debt | -1883 | -545.9 | -42.2 | -391.7 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 69 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 30.66 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | -2.83 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 11.66 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | -9.4 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | -10.03 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0.62 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | -31.58 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 55.85 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -239.04 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0.32 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | -75.75 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 96.42 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0.18 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -217.87 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | -290.19 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | -41.06 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 249.66 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -81.59 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 56.71 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -186.91 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 2926.25 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3113.16 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 55.85 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | -239.04 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | -183.19 | 55.4 | -86.5 | -150.4 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1188.98 | 1028.4 | 945.8 | 1338.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 445.22 | 365.6 | 309.4 | 491.3 | |||||||||||
income-statement-row.row.gross-profit | 743.76 | 662.8 | 636.4 | 847.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 103.52 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 58.01 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 461.49 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 105.38 | 110.5 | 46.5 | -11.1 | |||||||||||
income-statement-row.row.operating-expenses | 730.11 | 679.6 | 765.2 | 786.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 1175.33 | 1045.1 | 1074.6 | 1277.8 | |||||||||||
income-statement-row.row.interest-income | 28.1 | 28.3 | 11.8 | 10 | |||||||||||
income-statement-row.row.interest-expense | 22.92 | 22.6 | 13.8 | 9.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 461.49 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -0.98 | -17.5 | -1.9 | -51.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 105.38 | 110.5 | 46.5 | -11.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -0.98 | -17.5 | -1.9 | -51.1 | |||||||||||
income-statement-row.row.interest-expense | 22.92 | 22.6 | 13.8 | 9.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 7.41 | 106.6 | 122.9 | 79.9 | |||||||||||
income-statement-row.row.ebitda-caps | 84.96 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 77.55 | 57.6 | 454.8 | 84.2 | |||||||||||
income-statement-row.row.income-before-tax | 76.57 | 40.1 | 452.9 | 33.2 | |||||||||||
income-statement-row.row.income-tax-expense | 11.22 | 13.6 | 103.2 | 6.5 | |||||||||||
income-statement-row.row.net-income | 69 | 30.2 | 351 | 29.3 |
Често задавани въпроси
Какво е Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) общи активи?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) общите активи са 3276788333.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 580311209.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.591.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.591.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.058.
Какъв е общият приход на предприятието?
Общият приход е 0.065.
Каква е Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 30210042.000.
Какъв е общият дълг на фирмата?
Общият дълг е 656726080.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 679551269.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 1047468430.000.